Gamida Cell Ltd (GMDAQ)

May 24, 2024 - GMDAQ was delisted (reason: shares cancelled)
0.0170
0.00 (0.00%)
Last trade price
Market Cap 1.87M
Revenue (ttm) 1.78M
Net Income (ttm) -63.00M
Shares Out 110.05M
EPS (ttm) -0.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 332,754
Open n/a
Previous Close 0.0170
Day's Range 0.0170 - 0.0170
52-Week Range 0.0080 - 0.0250
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About GMDAQ

Gamida Cell Ltd. researches, develops, and commercializes cell therapies. The company offers Omisirge (omidubicel-onlv), a cell therapy for use in treatment of patients with hematologic malignancies and severe aplastic anemia. Its product candidate includes GDA-201, an investigational NK cell-based cancer immunotherapy, for the treatment of hematologic and solid tumors, as well as to treat follicular and diffuse large B-cell lymphomas which is in phase 1 of phase1/2 clinical trial. The company was incorporated in 1998 and is based in Boston, Ma... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 26, 2018
Employees 145
Stock Exchange OTCMKTS
Ticker Symbol GMDAQ
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management

BOSTON--(BUSINESS WIRE)--Gamida Cell (the “Company”), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced new executive leadership following a successful restructu...

27 days ago - Business Wire

Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management

Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge ® (omidubicel-onlv)

3 months ago - GlobeNewsWire

Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update

Company announces commencement of restructuring process  supported by Highbridge Capital Management Continued progress of launch of Omisirge ® (omidubicel-onlv), with the delivery of six units in 2023...

3 months ago - GlobeNewsWire

Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results

BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its f...

4 months ago - GlobeNewsWire

Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge ® (omidubicel...

5 months ago - GlobeNewsWire

Gamida Cell Actively Pursuing Strategic Alternatives

BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it is actively pursuing strategic al...

6 months ago - GlobeNewsWire

Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it will present new data on its FDA ...

6 months ago - GlobeNewsWire

Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023

BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, is hosting a virtual fireside chat with thought lead...

8 months ago - GlobeNewsWire

Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference

BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will presen...

8 months ago - GlobeNewsWire

Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update

Company continues to advance launch, reports initial revenue from Omisirge ® (omidubicel-onlv)

8 months ago - GlobeNewsWire

Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Data further characterize the mechanism for Gamida Cell's proprietary nicotinamide (NAM) technology's expansion and enhancement of cells Data further characterize the mechanism for Gamida Cell's propr...

9 months ago - GlobeNewsWire

Gamida Cell to Report Third Quarter 2023 Financial Results

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its fi...

9 months ago - GlobeNewsWire

Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced new early data in 10 patients with CD20 positive non-...

9 months ago - Business Wire

Gamida Cell Issues Update on Israel Operations

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today issued an update on its operations in Israel. “We remain profou...

9 months ago - Business Wire

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.

Other symbols: CGENKMDAPLXTAROTEVA
10 months ago - Market Watch

Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Off...

10 months ago - Business Wire

Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that it will be presenting at the Society for Immunot...

10 months ago - Business Wire

First Patient Receives Gamida Cell's Omisirge™ (omidubicel-onlv)

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the first patient has received a stem cell trans...

10 months ago - Business Wire

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highl...

11 months ago - Business Wire

Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for t...

1 year ago - Business Wire

Gamida Cell to Report Second Quarter 2023 Financial Results

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results f...

1 year ago - Business Wire

Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell's Omisirge® (omidubicel-onlv)

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the publication in press of a prospective sub-study o...

1 year ago - Business Wire

STAND UP TO CANCER NAMES JULIAN ADAMS, Ph.D., CHIEF SCIENCE OFFICER

Veteran Oncology Researcher to Guide Investment in Breakthrough Cancer Treatments LOS ANGELES , July 10, 2023 /PRNewswire/ -- Stand Up To Cancer® (SU2C) today announced that Julian Adams, Ph.D., a lon...

1 year ago - PRNewsWire

Gamida Cell To Host Investor Day

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, will host an Investor Day on Thursday, June 29, 2023 beginning at 8 a...

1 year ago - Business Wire

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Michele Korfin, Chief Operating and Chief Commer...

1 year ago - Business Wire